Cargando…

EGFR‐mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib

Here, we report a rare case involving a 66‐year‐old man with epidermal growth factor receptor (EGFR)‐mutant lung adenocarcinoma and antisynthetase syndrome (ASS) treated with osimertinib. The patient presented with respiratory failure and bilateral pulmonary opacities; he was diagnosed with ASS acco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hara, Reina, Kanazu, Masaki, Iwai, Ami, Kuge, Tomoki, Ishijima, Mikako, Uenami, Takeshi, Akazawa, Yuki, Yano, Yukihiro, Yamaguchi, Toshihiko, Mori, Masahide
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2021
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088957/ https://www.ncbi.nlm.nih.gov/pubmed/33682361 http://dx.doi.org/10.1111/1759-7714.13920

Ejemplares similares

Safety and effectiveness of pirfenidone combined with carboplatin‐based chemotherapy in patients with idiopathic pulmonary fibrosis and non‐small cell lung cancer: A retrospective cohort study
por: Yamamoto, Yuji, et al.
Publicado: (2020)

Expectoration of tonsillar metastasis of pulmonary pleomorphic carcinoma after pseudoprogression: A case report
por: Kuge, Tomoki, et al.
Publicado: (2021)

Hyperprogressive disease in patients with non‐small cell lung cancer treated with nivolumab: A case series
por: Kanazu, Masaki, et al.
Publicado: (2018)

Bronchial ethanol injection therapy for airway obstruction in lung cancer patients
por: Okabe, Fukuko, et al.
Publicado: (2021)

Case series of pleomorphic carcinomas of the lung treated with nivolumab
por: Kanazu, Masaki, et al.
Publicado: (2017)

Radiation Pneumonitis with Eosinophilic Alveolitis in a Lung Cancer Patient
por: Hosono, Yuki, et al.
Publicado: (2017)

Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune‐related adverse effect: A case report
por: Edahiro, Ryuya, et al.
Publicado: (2019)

Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study
por: Yano, Yukihiro, et al.
Publicado: (2018)

Non‐small cell lung cancer with tumor proportion score > 90% could increase the risk of severe immune‐related adverse events in first‐line treatments with immune checkpoint inhibitors: A retrospective single‐center study
por: Akazawa, Yuki, et al.
Publicado: (2022)

Radiographic change over 11 years in a patient with asbestos‐related pleural disease
por: Hara, Reina, et al.
Publicado: (2020)

Febrile neutropenia with bacterial paronychia
por: Hosono, Yuki, et al.
Publicado: (2018)

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
por: Gen, Soei, et al.
Publicado: (2022)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course
por: Cavagna, Lorenzo, et al.
Publicado: (2019)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib
por: Nishiyama, Akihiro, et al.
Publicado: (2020)

Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
por: Lee, Jiyun, et al.
Publicado: (2022)

Effectiveness of EGFR tyrosine kinase inhibitors in advanced non‐small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study
por: Kanazu, Masaki, et al.
Publicado: (2020)

Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients
por: Osa, Akio, et al.
Publicado: (2018)

A case of antisynthetase syndrome
por: Mavragani, Clio P., et al.
Publicado: (2020)

Antisynthetase Syndrome With Paraneoplastic Antibodies
por: Pokharel, Ashbina, et al.
Publicado: (2023)

In Antisynthetase Syndrome, ACPA Are Associated With Severe and Erosive Arthritis: An Overlapping Rheumatoid Arthritis and Antisynthetase Syndrome
por: Meyer, Alain, et al.
Publicado: (2015)

Successful Treatment of EGFR-Mutant Synchronous SCLC and Lung Adenocarcinoma With Osimertinib
por: Batra, Ullas, et al.
Publicado: (2020)

Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2019)

Metastatic Lung Tumors from Colorectal Cancer with EGFR Mutations That Responded to Osimertinib
por: Yanagisawa, Atsushi, et al.
Publicado: (2022)

Clinicopathological impact of VEGFR2 and VEGF‐C in patients with EGFR ‐major mutant NSCLC receiving osimertinib
por: Kaira, Kyoichi, et al.
Publicado: (2023)

The clinical phenotype associated with antisynthetase autoantibodies
por: Masiak, Anna, et al.
Publicado: (2020)

Echocardiographic characteristics of patients with antisynthetase syndrome
por: Bryan, Jaimie L., et al.
Publicado: (2022)

Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
por: Ye, Qiuyue, et al.
Publicado: (2023)

Glycogen synthase kinase‐3 inhibition overcomes epithelial‐mesenchymal transition‐associated resistance to osimertinib in EGFR‐mutant lung cancer
por: Fukuda, Koji, et al.
Publicado: (2020)

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance
por: Wang, Jiao‐Li, et al.
Publicado: (2022)

Successful Desensitization Treatment with Osimertinib after the Development of Osimertinib-induced Urticaria in a Patient Undergoing Treatment for Non-small Cell Lung Cancer Harboring the EGFR T790M Mutation
por: Makimoto, Go, et al.
Publicado: (2020)

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer
por: Roper, Nitin, et al.
Publicado: (2020)

ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
por: Ortega-Franco, Ana, et al.
Publicado: (2022)

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
por: Yamaguchi, Ou, et al.
Publicado: (2023)

6. A case of antisynthetase syndrome in pregnancy
por: Green, Lauren, et al.
Publicado: (2017)

Clinical Puzzles and Decision-Making in Antisynthetase Syndrome
por: Yehudina, Yelyzaveta, et al.
Publicado: (2021)

A multidisciplinary approach to the diagnosis of antisynthetase syndrome
por: Wells, Matthew, et al.
Publicado: (2022)

Antisynthetase Syndrome: The Classical Phenotype With a Twist
por: Betsikos, Achilleas, et al.
Publicado: (2023)

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
por: Zang, Hongjing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b1k5suqai1n9t18r002iio3uvj